Search results for "leukemia."

showing 10 items of 970 documents

A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood ‘high-risk’ acute lymphoblastic leukaemia:…

2002

The outcome of children with acute lymphoblastic leukaemia (ALL) and early relapse remains unsatisfactory. In January 1995, the AIEOP (Associazione Italiana di Oncologia ed Ematologia Pediatrica) group opened a trial for children with ALL in first isolated or combined bone marrow relapse defined at high risk according to the length of first remission and the immunophenotype. The treatment plan included the combination of a single high-dose idarubicin and high-dose cytarabine as induction therapy followed by an intensive consolidation and stem cell transplant (SCT). In total, 100 children from 16 Italian centres were enrolled; 80 out of the 99 evaluable patients (81%) achieved second complet…

medicine.medical_specialtyChemotherapybusiness.industrymedicine.drug_classmedicine.medical_treatmentHematologyHematopoietic stem cell transplantationmedicine.diseaseAntimetaboliteSurgerymedicine.anatomical_structureInternal medicineAcute lymphocytic leukemiaCytarabineMedicineIdarubicinBone marrowbusinessSurvival ratemedicine.drugBritish Journal of Haematology
researchProduct

Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults

1988

Abstract Thirty-six patients with relapsed acute lymphoblastic leukemia (ALL) and four with primary refractory ALL were treated with a regimen that included amsacrine, 200 mg/m2, intravenously daily for three days with cytarabine, 3 gm/m2, by infusion over three hours daily for five days. There were 27 remissions in the 36 relapsed patients and two in the four patients with primary refractory disease. Seventeen of the 23 patients with common ALL, four of the six with T-cell ALL, one of the three with B-cell ALL, and seven of eight whose cells were not characterized responded. Toxicity of this regimen was comparable to other reinduction regimens for ALL, but the side effects characteristic o…

medicine.medical_specialtyChemotherapymedicine.drug_classbusiness.industrymedicine.medical_treatmentImmunologyCell BiologyHematologymedicine.diseaseBiochemistryAntimetaboliteGastroenterologySurgeryRegimenRefractoryAcute lymphocytic leukemiaInternal medicineToxicitymedicineCytarabinebusinessAmsacrinemedicine.drugBlood
researchProduct

Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the …

2018

Summary Cytomegalovirus is one of the most important infections to occur after allogeneic haematopoietic stem cell transplantation (HSCT), and an increasing number of reports indicate that cytomegalovirus is also a potentially important pathogen in patients treated with recently introduced drugs for hematological malignancies. Expert recommendations have been produced by the 2017 European Conference on Infections in Leukaemia (ECIL 7) after a review of the literature on the diagnosis and management of cytomegalovirus in patients after HSCT and in patients receiving other types of therapy for haematological malignancies. These recommendations cover diagnosis, preventive strategies such as pr…

medicine.medical_specialtyCongenital cytomegalovirus infectionCytomegalovirusAntiviral AgentsLetermovirInternal medicinemedicineHumansIn patientGanciclovirLeukemiabusiness.industryHematopoietic Stem Cell TransplantationMaribavirmedicine.diseaseTransplantationClinical trialHaematopoiesisInfectious DiseasesHematologic NeoplasmsCytomegalovirus InfectionsPractice Guidelines as TopicBenzimidazolesRibonucleosidesStem cellbusinessmedicine.drugThe Lancet. Infectious diseases
researchProduct

All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive …

2005

Abstract Introduction: Response to first induction therapy is one of the most important prognostic factors in patients with adult myeloid leukemia (AML). Induction of CR or PR is the primary aim in these patients. Methods: Between 1993 and 2005 225 consecutive patients (median age: 48.4 yrs, range 16–60 yrs) treated within the AMLHD93 (n=45), AMLHD98A (n=157) and AMLSG 05-04 (n=23, still active) trials were evaluated. All patients had primary refractory AML after one cycle of ICE. The different salvage therapies were as follows: AMLHD93 sequential-HAM (S-HAM) for patients <55 years of age [cytarabine 3g/m2 bid. days 1,2,8,9, mitoxantrone 10mg/m2 days 3,4,10,11], HAM for patients >=55 …

medicine.medical_specialtyGemtuzumab ozogamicinmedicine.medical_treatmentImmunologySalvage therapyHematopoietic stem cell transplantationBiochemistryGastroenterology03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicineMedicine030304 developmental biology0303 health sciencesMitoxantronebusiness.industryMyeloid leukemiaCell BiologyHematologyOdds ratio3. Good healthSurgeryTransplantation030220 oncology & carcinogenesisCytarabinebusinessmedicine.drugBlood
researchProduct

Systemic mastocytosis. A GIMEMA multicenter survey

2006

Abstract To evaluate clinical and biological features, treatments and outcome of patients(pts) with Systemic Mastocytosis(SM). A retrospective study (1995–2006) about pts with SM admitted in 14 Italian hematology divisions in tertiary cares or university hospitals. 30 cases of SM were collected(median age 62 y.o.; M/F 14/16) and classified according to the WHO criteria: Mast Cell Leukemia in 14 pts, Aggressive SM in 12 and Indolent in 3; the remaining one had SM with associated clonal non-mast cell-lineage hematologic disease. Skin was the principal extramedullary organ involved (19 pts) followed by spleen(15), liver(13), and cardiovascular system(12). Molecular biology studies were perform…

medicine.medical_specialtyHematologybusiness.industrymedicine.medical_treatmentImmunologyAlpha interferonRetrospective cohort studyImatinibCell BiologyHematologyHematopoietic stem cell transplantationmedicine.diseaseMast cell leukemiaBiochemistryGastroenterologySurgeryHematologic diseaseInternal medicinemedicineSystemic mastocytosisbusinessmedicine.drug
researchProduct

Low-Dose Aclacinomycin and Intermediate-Dose Cytosine Arabinoside in Relapsed and Refractory Acute Myelogenous Leukemia

1990

Nineteen patients with relapsed or refractory acute myelogenous leukemia were treated with escalating doses of aclacinomycin (ACLA 20–30 mg/m2 daily for 5 days) and intermediate-dose cytosine arabinoside (Ara-C 1 g/m2 twice daily for 4 days). Most patients had received previous therapy with high- or intermediate-dose Ara-C plus mitoxantrone (HAM, IAM) and TAD (6-thioguanine, standard-dose cytosine arabinoside, and daunorubicin). Four patients had had repeated relapses and another three were treated for primary treatment failure following induction with HAM or I AM.

medicine.medical_specialtyMitoxantroneDaunorubicinbusiness.industryLow dosemedicine.diseaseGastroenterologyMyelogenouschemistry.chemical_compoundLeukemiaRefractorychemistryInternal medicinemedicinePrimary treatmentbusinessCytosinemedicine.drug
researchProduct

Pubertal maturation in girls treated for childhood acute leukaemia.

1991

Eleven girlds treated during childhood for acute leukaemia were followed up during their pubertal development. At each examination weight, height, pubertal stage, FSH, LH, oestradiol, testosterone, androstenedione and dehydroepiandrosterone sulphate levels were evaluated. Clinical and endocrinological studies were performed according to age and pubertal stage and compared to those of healthy girls matched for age and pubertal stage. Results showed that pubertal maturation and gonadal function were not affected by oncotherapy; however menarche was attained earlier. Early menarche was explained by the overweight of treated girls during early puberty. No evidence of early hypothalamic activati…

medicine.medical_specialtyOverweightPubertal stageEarly menarcheInternal medicineMedicineEndocrine systemHumansAndrostenedioneChildTestosteroneMenarchebusiness.industryBody WeightPubertyAge FactorsPrecursor Cell Lymphoblastic Leukemia-LymphomaBody HeightHormonesLeukemia Myeloid AcuteEndocrinologyEl NiñoChild PreschoolPediatrics Perinatology and Child HealthMenarcheFemalemedicine.symptombusinessFollow-Up StudiesEuropean journal of pediatrics
researchProduct

Recent epidemiological studies on ionizing radiation and childhood cancer in Germany.

1998

The results from recent epidemiological studies based on the German Childhood Cancer Registry are summarized.An oecological study covers 16 years' incidence of childhood malignancies in areas surrounding nuclear facilities and in matched control regions. Two population-based case control studies explore potential risk factors of childhood leukaemia in the state of Lower Saxony (1988 93) and in all western states of Germany (1992-94).There was no increased incidence of childhood leukaemia and other malignancies in the vicinity of nuclear installations. X-ray examinations during pregnancy and in early childhood were not associated with an increased risk of childhood leukaemia. There were no d…

medicine.medical_specialtyPediatricsNeoplasms Radiation-InducedPopulationCohort StudiesPregnancyRisk FactorsGermanyRadiation IonizingEpidemiologyMedicineHumansRadiology Nuclear Medicine and imagingEarly childhoodRisk factoreducationChildLeukemia Radiation-InducedChildhood Cancer Registryeducation.field_of_studyPregnancyRadiological and Ultrasound Technologybusiness.industryIncidence (epidemiology)Case-control studyRadiobiologymedicine.diseaseRadiographyCase-Control StudiesChild PreschoolPrenatal Exposure Delayed EffectsFemalebusinessRadioactive Hazard ReleasePower PlantsInternational journal of radiation biology
researchProduct

High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) Has a Significant but Transient Impact on Quality of Life: Lessons Fr…

2011

Abstract Abstract 1989 Objective: High-dose therapy (HDT) and ASCT is the standard of care in a variety of hematologic malignancies. Whereas for some indications a survival advantage for HDT and ASCT has been demonstrated, a benefit only in terms of better progression-free survival has been shown for CLL. Because of this the quality of life (QoL) deserves particular attention. QoL assessment was a major focus of a randomized controlled EBMT-Intergroup trial on the value of HDT compared to observation in first or second remission of CLL (Michallet, Blood, 2011). Methods: 222 patients were enrolled into the study and allocated to either ASCT or observation. In the transplant arm, 72% received…

medicine.medical_specialtyRandomizationIntention-to-treat analysisbusiness.industrymedicine.medical_treatmentChronic lymphocytic leukemiaImmunologyCell BiologyHematologyHematopoietic stem cell transplantationmedicine.diseaseBiochemistryTransplantationQuality of lifeChronic leukemiaInternal medicineCohortmedicinebusiness
researchProduct

Indomethacin treatment in amphotericin B induced nephrogenic diabetes insipidus.

1994

Nephrogenic diabetes insipidus (NDI) is a serious side effect of various drugs. Elevated renal prostaglandin E2 levels have been found in patients with lithium-induced NDI and have been implicated in the pathogenesis. We report the case of a patient who developed NDI following treatment with amphotericin B. Prostaglandin levels were elevated. Indomethacin had an antidiuretic effect and normalized prostaglandin levels.

medicine.medical_specialtySide effectVasopressinsIndomethacinProstaglandinDiabetes Insipidus NephrogenicKidneyLeukemia Myelomonocytic AcutePathogenesischemistry.chemical_compoundAmphotericin BInternal medicineAmphotericin BDrug DiscoveryMedicineHumansProstaglandin E2Genetics (clinical)business.industryGeneral MedicineMiddle Agedmedicine.diseaseNephrogenic diabetes insipidusDiuresisEndocrinologychemistryDiabetes insipidusToxicityProstaglandinsTobramycinMolecular Medicinelipids (amino acids peptides and proteins)Femalebusinessmedicine.drugThe Clinical investigator
researchProduct